SCHEMBL20596534

SCHEMBL20596534

COc1ccc(-c2cccn3cc(CC(=O)Nc4ccc(Cl)nc4N)nc23)c(Cl)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 4/20 0.39
▸ ALDH1A1 P00352 2/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ KMT2A Q03164 2/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ MAPK1 P28482 1/20 0.38
▸ USP2 O75604 1/20 0.38
▸ HSP90AA1 P07900 1/20 0.37
▸ HSP90AB1 P08238 1/20 0.37
▸ CYP1A2 P05177 1/20 0.37
▸ CYP2C9 P11712 1/20 0.37
▸ CYP2C19 P33261 1/20 0.37
▸ MAPT P10636 2/20 0.37
▸ TP53 P04637 2/20 0.37
▸ KDM4E B2RXH2 1/20 0.37
▸ CA12 O43570 1/20 0.36
▸ CA1 P00915 1/20 0.36
▸ CA2 P00918 1/20 0.36
▸ CA9 Q16790 1/20 0.36
▸ ALDH1A3 P47895 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30145217 0.83 ALDH1A3 (0.42) ALDH1A1HSP90AA1HSP90AB1CYP1A2CYP2C19
SCHEMBL30145295 0.82 ALDH1A3 (0.43) ALDH1A1MAPK1HSP90AA1HSP90AB1CYP1A2
SCHEMBL20595835 0.81 MEN1 (0.38) LMNAALDH1A1SMN1; SMN2KMT2AMEN1
SCHEMBL20596647 0.80 MEN1 (0.36) LMNAALDH1A1SMN1; SMN2KMT2AMEN1
SCHEMBL20596490 0.80 MARS2 (0.42) LMNAALDH1A1SMN1; SMN2KMT2AMEN1
SCHEMBL20596557 0.78 MAPT (0.43) LMNAALDH1A1SMN1; SMN2KMT2AMEN1
SCHEMBL20596051 0.78 CA12 (0.37) LMNAALDH1A1SMN1; SMN2KMT2AMEN1
SCHEMBL20596076 0.77 NOD2 (0.38) LMNAALDH1A1SMN1; SMN2KMT2AMEN1
SCHEMBL23419269 0.76 MEN1 (0.40) LMNAALDH1A1SMN1; SMN2KMT2AMEN1
SCHEMBL20595923 0.75 CYP1A2 (0.39) LMNAALDH1A1SMN1; SMN2KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11584744-B2 Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them UNIVERSITY OF WASHINGTON (US) 2023-02-21 — — US disclosed
US-11584744-B2 Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them UNIVERSITY OF WASHINGTON (US) 2023-02-21 — — US disclosed
US-20210155617-A1 INHIBITORS OF TYPE l METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM UNIVERSITY OF WASHINGTON 2021-05-27 — — US disclosed
US-20210155617-A1 INHIBITORS OF TYPE l METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM UNIVERSITY OF WASHINGTON 2021-05-27 — — US disclosed
WO-2018237349-A1 INHIBITORS OF TYPED 1 METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM UNIVERSITY OF WASHINGTON (US) 2018-12-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11584744-B2 Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them AARS1, EMG1, GARS1 LMNA 3342/4885ALDH1A1 1461/4885SMN1; SMN2 1129/4885
US-20210155617-A1 INHIBITORS OF TYPE l METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM AARS1, GARS1, MTR LMNA 2770/4885ALDH1A1 2337/4885SMN1; SMN2 1329/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback